B. Riley Securities Reiterates Buy on Journey Medical, Raises Price Target to $15
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and raises the price target from $12 to $15.
Read original at benzingaStocks · News reference
Journey Medical Q2 EPS $(0.01) Beats $(0.02) Estimate, Sales $17.839M Miss $18.366M Estimate
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 93.75 percent increase over losses of $(0.16) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 8:02 PM
- Checked
- Aug 12, 2026, 8:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading